Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Investing.com -- Viatris Inc. (NASDAQ:VTRS) stock fell 3.6% after the company announced that its Phase 3 study of MR-139 for blepharitis did not meet its primary endpoint.
The randomized, double-masked, vehicle-controlled trial evaluated pimecrolimus 0.3% (MR-139) ophthalmic ointment in patients with blepharitis. According to the company, the study failed to achieve its primary goal of complete resolution of debris after six weeks of twice daily dosing.
Philippe Martin, Viatris Chief R&D Officer, stated that the company is "evaluating the appropriate next steps for the Phase 3 program, which may include revising the planned additional Phase 3 study."
The trial included 477 patients who were randomized to receive either MR-139 or placebo, self-administered to the eyelids twice daily over a 12-week period.
Despite this setback, Viatris emphasized its continued focus on delivering novel therapies such as Tyrvaya and RYZUMVI, while advancing its pipeline addressing unmet needs in anterior segment conditions. The company recently reported positive top-line results from two other Phase 3 trials: the LYNX-2 trial of MR-142 in keratorefractive patients and the VEGA-3 Trial of MR-141 for treating presbyopia.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.